Voss, M. H., Hierro, C., Heist, R. S., Cleary, J. M., Meric-Bernstam, F., Tabernero, J., . . . Baselga, J. (2019). A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. Clinical cancer research, 25(9), 2699. https://doi.org/10.1158/1078-0432.CCR-18-1959
Chicago-Zitierstil (17. Ausg.)Voss, Martin H., et al. "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations." Clinical Cancer Research 25, no. 9 (2019): 2699. https://doi.org/10.1158/1078-0432.CCR-18-1959.
MLA-Zitierstil (9. Ausg.)Voss, Martin H., et al. "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations." Clinical Cancer Research, vol. 25, no. 9, 2019, p. 2699, https://doi.org/10.1158/1078-0432.CCR-18-1959.